EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prophylactic HPV Vaccination in Gynaecological Practice: Recommendations, Practices, and Challenges Reported in the ESGO-PERCH HPV Survey

Joanna Kacperczyk-Bartnik iD, Marc Arbyn iD, Sophie Denoël iD, Esra Bilir, Nina Dhollander, Zoia Razumova iD, Khayal Gasimli, Andrej Cokan, Houssein El Hajj iD, Tibor Andrea Zwimpfer iD, Maria Kyrgiou, Murat Gultekin und 1 weitere

Vaccines · 16.03.2026 · 14 (3) · 269

DOI: 10.3390/vaccines14030269 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Vaccines, online erschienen am 16.03.2026. Verfasst von Joanna Kacperczyk-Bartnik und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynaecological Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: EU4Health, EU4Health Programme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: HPV vaccination is highly effective in preventing HPV-related cancers when administered before viral exposure. However, vaccination practices for patients already diagnosed with gynaecological cancers remain poorly characterized. Understanding clinicians’ perspectives and barriers is essential for optimizing preventive strategies in oncologic care.

Methods

We conducted an international, web-based survey among members of the European Society of Gynaecological Oncology (ESGO) and the European Network of Young Gynaecological Oncologists (ENYGO). The questionnaire explored clinicians’ attitudes, practices, and perceived obstacles regarding HPV vaccination in patients with gynaecological cancer or pre-invasive disease across multiple clinical scenarios and age groups.

Results

A total of 149 respondents from 33 countries completed the survey. Most clinicians supported HPV vaccination for patients treated for cervical precancer (78–82% for patients under 45 years), and even for invasive cervical cancer (57–62%). Recommendations varied by patients’ age, cancer type, and treatment status. For endometrial and ovarian cancer, endorsement ranged from 16% to 53%, depending on patient age. Timing of vaccination was a point of divergence: some clinicians favoured vaccination immediately after treatment for CIN2+, while others recommended delaying vaccination depending on HPV test results. Reported barriers discouraging HPV vaccination recommendations included misinformation (69.8%), lack of patient education materials (52.3%), and time constraints (48.3%), alongside economic factors and uncertainty about efficacy in oncologic settings.

Conclusions

The survey shows that HPV vaccination is often recommended beyond evidence-supported indications. Randomized trials have not demonstrated a reduction in CIN2+ recurrence with adjuvant vaccination, and no evidence supports vaccination in women with invasive gynaecological cancers. These findings reveal a gap between clinical practice and available evidence, highlighting the need for clearer, evidence-based guidance.

Schlagwörter

Stichwörter der Autor:innen

endometrial neoplasmshuman papillomavirus virusesovarian neoplasmsprimary preventionrecurrencesecondary preventionuterine cervical dysplasiauterine cervical neoplasmsvaccination

Autor:innen und Institutionen

  • Department of Gynaecological Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.
  • II Department of Obstetrics, Gynaecology and Gynaecological Oncology, Medical University of Warsaw, 00-315 Warsaw, Poland.
  • Unit of Cancer Epidemiology, Belgian Cancer Centre, Sciensano, 1050 Brussels, Belgium.
  • Department of Human Structure and Repair, Faculty of Medicine and Health Sciences, University Ghent, 9000 Ghent, Belgium.
  • Department of Gynecologic Oncology, Koç University School of Medicine Department, 34450 Istanbul, Türkiye.
  • School of Medicine, American University of Sovereign Nations, Sacaton, AZ 85147, USA.

ORCID-Profile: Joanna Kacperczyk-Bartnik, Marc Arbyn, Sophie Denoël, Zoia Razumova, Houssein El Hajj, Tibor Andrea Zwimpfer, Nicolò Bizzarri

Förderung

  • EU4Health
  • EU4Health Programme

Zitieren

APA

Kacperczyk-Bartnik, J., Arbyn, M., Denoël, S., Bilir, E., Dhollander, N., Razumova, Z., Gasimli, K., Cokan, A., Hajj, H. E., Zwimpfer, T. A., Kyrgiou, M., Gultekin, M., & Bizzarri, N. (2026). Prophylactic HPV Vaccination in Gynaecological Practice: Recommendations, Practices, and Challenges Reported in the ESGO-PERCH HPV Survey. Vaccines, 14(3), 269. https://doi.org/10.3390/vaccines14030269

Vancouver

Kacperczyk-Bartnik J, Arbyn M, Denoël S, Bilir E, Dhollander N, Razumova Z, et al. Prophylactic HPV Vaccination in Gynaecological Practice: Recommendations, Practices, and Challenges Reported in the ESGO-PERCH HPV Survey. Vaccines. 2026;14(3):269. doi:10.3390/vaccines14030269

BibTeX
@article{KacperczykBartnik2026,
  author = {Kacperczyk-Bartnik, Joanna and Arbyn, Marc and Denoël, Sophie and Bilir, Esra and Dhollander, Nina and Razumova, Zoia and Gasimli, Khayal and Cokan, Andrej and Hajj, Houssein El and Zwimpfer, Tibor Andrea and Kyrgiou, Maria and Gultekin, Murat and Bizzarri, Nicolò},
  title = {Prophylactic HPV Vaccination in Gynaecological Practice: Recommendations, Practices, and Challenges Reported in the ESGO-PERCH HPV Survey},
  journal = {Vaccines},
  year = {2026},
  volume = {14},
  number = {3},
  pages = {269},
  doi = {10.3390/vaccines14030269}
}
Kostenlos starten →